NO20015016L - New polymorphic forms of an antidiabetic agent; process for their preparation and pharmaceutical compositions containing them - Google Patents

New polymorphic forms of an antidiabetic agent; process for their preparation and pharmaceutical compositions containing them

Info

Publication number
NO20015016L
NO20015016L NO20015016A NO20015016A NO20015016L NO 20015016 L NO20015016 L NO 20015016L NO 20015016 A NO20015016 A NO 20015016A NO 20015016 A NO20015016 A NO 20015016A NO 20015016 L NO20015016 L NO 20015016L
Authority
NO
Norway
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
polymorphic forms
antidiabetic agent
Prior art date
Application number
NO20015016A
Other languages
Norwegian (no)
Other versions
NO20015016D0 (en
Inventor
Om Reddy Gaddam
Rajendra Kumar Potlapally
Raju Sirisilla
Vyas Krishnamurthi
Sreenivasa Rao Dharmaraja
Ramabhadra Sarma Mamillapalli
Original Assignee
Reddy Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/000681 external-priority patent/WO2000063191A1/en
Application filed by Reddy Research Foundation filed Critical Reddy Research Foundation
Publication of NO20015016D0 publication Critical patent/NO20015016D0/en
Publication of NO20015016L publication Critical patent/NO20015016L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO20015016A 1999-04-16 2001-10-15 New polymorphic forms of an antidiabetic agent; process for their preparation and pharmaceutical compositions containing them NO20015016L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB1999/000681 WO2000063191A1 (en) 1999-04-16 1999-04-16 Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
IN436MA1999 1999-04-19
PCT/IB2000/000470 WO2000063192A1 (en) 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
NO20015016D0 NO20015016D0 (en) 2001-10-15
NO20015016L true NO20015016L (en) 2001-12-11

Family

ID=26318745

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015016A NO20015016L (en) 1999-04-16 2001-10-15 New polymorphic forms of an antidiabetic agent; process for their preparation and pharmaceutical compositions containing them

Country Status (17)

Country Link
EP (1) EP1171430A1 (en)
CN (1) CN1351597A (en)
AU (1) AU3831300A (en)
BG (1) BG106022A (en)
BR (1) BR0010683A (en)
CA (1) CA2370401A1 (en)
CZ (1) CZ20013711A3 (en)
EE (1) EE200100529A (en)
HR (1) HRP20010748A2 (en)
HU (1) HUP0200758A3 (en)
IL (1) IL145958A0 (en)
MX (1) MXPA01010472A (en)
NO (1) NO20015016L (en)
PL (1) PL351492A1 (en)
RU (1) RU2001130883A (en)
TR (1) TR200103851T2 (en)
WO (1) WO2000063192A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309818T1 (en) 2000-03-08 2005-12-15 Novo Nordisk As LOWERING SERUM CHOLESTEROL
US6897199B2 (en) * 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
IL162620A0 (en) 2001-12-21 2005-11-20 Novo Nordisk As Amide derivatives as gk activators
SI1505066T1 (en) * 2002-04-19 2007-04-30 Faes Farma Sa Polymorph of acid 4-(2-(4-(1-(2-ethoxyethyl)-1h-benzimidazole-2-il)-1-piperidinyl)ethyl)-alpha, alpha-dimethyl-benzeneacetic
EP2471533A1 (en) 2002-06-27 2012-07-04 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
JP2007503453A (en) 2003-05-14 2007-02-22 ノボ　ノルディスク　アクティーゼルスカブ Novel compounds for treating obesity
BRPI0414890A (en) 2003-09-30 2006-12-12 Novo Nordisk As compound, methods of retarding the progression of igt to type 2 diabetes, and type 2 diabetes to insulin-requiring diabetes, to treat obesity or prevent overweight, to regulate appetite, to induce satiety, to prevent weight gain. weight, increasing energy expenditure, and treating a disease or condition, pharmaceutical composition, and use of a compound
EP1694356B1 (en) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
PL1723128T3 (en) 2004-01-06 2013-04-30 Novo Nordisk As Heteroaryl-ureas and their use as glucokinase activators
US20080113944A1 (en) 2004-05-04 2008-05-15 Novo Nordisk A/S Novel Indole Derivatives
WO2005120492A1 (en) 2004-06-11 2005-12-22 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
CN101060856B (en) 2004-11-22 2011-01-19 诺和诺德公司 Soluble, stable insulin-containing formulations with a protamine salt
MX2007006420A (en) 2004-12-03 2007-07-19 Novo Nordisk As Heteroaromatic glucokinase activators.
BRPI0613564A2 (en) 2005-07-04 2011-01-18 Novo Nordisk As compounds, their uses in the preparation of pharmaceutical compositions and pharmaceutical compositions comprising the same
BRPI0612996A2 (en) 2005-07-14 2010-12-14 Novo Nordisk As urea glucokinase activators
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
SI1951658T1 (en) 2005-11-17 2012-11-30 Lilly Co Eli Glucagon receptor antagonists, preparation and therapeutic uses
SG170785A1 (en) 2006-03-28 2011-05-30 Transtech Pharma Benzothiazoles having histamine h3 receptor activity
AU2007267197B2 (en) 2006-05-29 2011-12-01 High Point Pharmaceuticals, Llc 3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist
EP2097388B1 (en) 2006-11-15 2011-09-07 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
EP2086951B1 (en) 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
EP2099777B1 (en) 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
JP2010013472A (en) * 2009-09-09 2010-01-21 Faes Farma Sa POLYMORPH OF 4-[2-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-1-PIPERIDINYL] ETHYL-alpha,alpha-DIMETHYL BENZENOACETIC ACID
BR112012021231A2 (en) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
CA2792663A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
CA2830974A1 (en) 2011-03-28 2012-10-04 Jesper F. Lau Novel glucagon analogues
AR088161A1 (en) 2011-09-23 2014-05-14 Novo Nordisk As GLUCAGON ANALOGS
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
CN105307672B (en) 2013-04-18 2021-01-05 诺和诺德股份有限公司 Stable, extended GLP-1/glucagon receptor co-agonists for medical use
JP2017525656A (en) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス GLP-1 / glucagon receptor co-agonist for medical use
MA49883A (en) 2017-03-15 2021-04-21 Novo Nordisk As BICYCLIC COMPOUNDS SUITABLE TO BIND TO MELANOCORTIN 4 RECEPTOR
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
IN182496B (en) * 1996-02-20 1999-04-17 Reddy Research Foundation
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2746099B1 (en) * 1996-03-13 1998-04-30 IMPROVED PROCESS FOR THE PREPARATION OF 3- (10-PHENOTHIAZYL) -PROPANOIC OR 3- (10-PHENOXAZYL) -PROPANOIC ACID DERIVATIVES
EP0844997A1 (en) * 1996-06-19 1998-06-03 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999020614A1 (en) * 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
AU1887999A (en) * 1998-01-29 1999-08-16 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EE200100529A (en) 2002-12-16
CA2370401A1 (en) 2000-10-26
EP1171430A1 (en) 2002-01-16
TR200103851T2 (en) 2002-04-22
HRP20010748A2 (en) 2003-02-28
MXPA01010472A (en) 2002-05-06
BG106022A (en) 2002-04-30
BR0010683A (en) 2003-07-01
PL351492A1 (en) 2003-04-22
HUP0200758A3 (en) 2003-07-28
CZ20013711A3 (en) 2002-07-17
RU2001130883A (en) 2004-03-20
IL145958A0 (en) 2002-07-25
HUP0200758A2 (en) 2002-07-29
CN1351597A (en) 2002-05-29
NO20015016D0 (en) 2001-10-15
AU3831300A (en) 2000-11-02
WO2000063192A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
NO20015016L (en) New polymorphic forms of an antidiabetic agent; process for their preparation and pharmaceutical compositions containing them
NO20003764D0 (en) New <beta> -carboline compounds, process of their preparation and pharmaceutical compositions containing them
NO20011478L (en) New N- (iminomethyl) amine derivatives, process for their preparation, use as medicaments and compositions containing them
NO20014102L (en) New Tricyclic Compounds and Their Uses in Medicine, Methods of Their Preparation and Pharmaceutical Composition Containing Them
NO996250D0 (en) New Hydrazide Compounds, Methods of their Preparation and Pharmaceutical Compositions Containing Them
NO20013254L (en) New Diphenylurea Compounds, Methods of their Preparation and Pharmaceutical Compositions Containing Them
NO971862L (en) Novel Inhibitors of Metalloprotease, Process of their Preparation and Pharmaceutical Compositions Containing Them
NO20032734D0 (en) New 1,2-diphenyllazetidinone derivatives, process for their preparation, drugs containing said compounds and use of these for the treatment of diseases from lipid metabolism
NO20010522L (en) New piperidine-4-sulfonamide compounds, process of their preparation and pharmaceutical compositions containing them
NO20026154L (en) New Substituted Phthalides, Methods of their Preparation and Pharmaceutical Compositions Containing Them
NO20013206D0 (en) New 1,1- and 1,2-disubstituted cyclopropane compounds, process of their preparation, and pharmaceutical compositions containing them
NO20015058D0 (en) New ribose-substituted aromatic amides, method of preparation, and use thereof as medicaments
EE200300553A (en) Piperidine carboxamide derivatives, process for their preparation, and pharmaceutical compositions containing them
NO20034614L (en) New [3,4-a: 3,4-c] carbazole compounds, processes for their preparation and pharmaceutical compositions containing them
DK1150970T3 (en) (1-phenacy-3-phenyl-3-piperidylethyl) piperidine derivatives, process for their preparation and pharmaceutical compositions containing them
EE200100499A (en) Novel morpholine derivatives, process for their preparation and pharmaceutical compositions containing them
NO961677D0 (en) New Cyclohexane Compounds, Methods of their Preparation and Pharmaceutical Compositions Containing Them
NO20013710L (en) New Benzothiadiazine Compounds, Methods of their Preparation, and Pharmaceutical Compositions Containing Them
NO20016069L (en) Novel bicyclic amino-pyrazinone compounds, process of their preparation, and pharmaceutical compositions containing them
NO20052330D0 (en) Novel substituted [1,4] benzodioxino [2,3] isoindole compounds, processes for their preparation and pharmaceutical compositions containing them
NO20011862L (en) Novel heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds, process of their preparation and pharmaceutical compositions containing them
NO20025393D0 (en) Optis 2-aminotetraline derivatives, process for their preparation and therapeutic application of pharmaceutical use of pharmaceutical compositions containing them
NO20042447L (en) New benzo (a) pyranol [3,2-h] acridin-7-one compounds, process for their preparation and pharmaceutical compositions containing them
NO20020262L (en) New Cyclohepten Compounds, Methods of their Preparation and Pharmaceutical Compositions Containing Them
NO20043532L (en) New 3-aryl-2,5-dihydroxy-1,4-benzoquinone compounds, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application